UK biobank: Enhanced assessment of the epidemiology and long-term impact of coronavirus disease-2019
Cambridge Prisms: Precision Medicine · 2023
DOI: 10.1017/pcm.2023.18 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cambridge Prisms: Precision Medicine, 2023. Verfasst von Qi Feng und 15 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Population Health, Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University o…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
UK Biobank is an intensively characterised prospective cohort of 500,000 adults aged 40–69 years when recruited between 2006 and 2010. The study was established to enable researchers worldwide to undertake health-related research in the public interest. The existence of such a large, detailed prospective cohort with a high degree of participant engagement enabled its rapid repurposing for coronavirus disease-2019 (COVID-19) research. In response to the pandemic, the frequency of updates on hospitalisations and deaths among participants was immediately increased, and new data linkages were established to national severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing and primary care health records to facilitate research into the determinants of severe COVID-19. UK Biobank also instigated several sub-studies on COVID-19. In 2020, monthly blood samples were collected from approximately 20,000 individuals to investigate the distribution and determinants of SARS-CoV-2 infection, and to assess the persistence of antibodies following infection with another blood sample collected after 12 months. UK Biobank also performed repeat imaging of approximately 2,000 participants (half of whom had evidence of previous SARS-CoV-2 infection and half did not) to investigate the impact of the virus on changes in measures of internal organ structure and function. In addition, approximately 200,000 UK Biobank participants took part in a self-test SARS-CoV-2 antibody sub-study (between February and November 2021) to collect objective data on previous SARS-CoV-2 infection. These studies are enabling unique research into the genetic, lifestyle and environmental determinants of SARS-CoV-2 infection and severe COVID-19, as well as their long-term health effects. UK Biobank’s contribution to the national and international response to the pandemic represents a case study for its broader value, now and in the future, to precision medicine research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Oxford Population Health, Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.
- UK Biobank, Stockport, Greater Manchester, UK.
ORCID-Profile: Qi Feng
Förderung
- Wellcome Trust
Zitieren
APA
Feng, Q., Lacey, B., Bešević, J., Omiyale, W., Conroy, M., Starkey, F., Calvin, C., Callen, H., Bramley, L., Welsh, S., Young, A., Effingham, M., Young, A., Collins, R., Holliday, J., & Allen, N. (2023). UK biobank: Enhanced assessment of the epidemiology and long-term impact of coronavirus disease-2019. Cambridge Prisms: Precision Medicine. https://doi.org/10.1017/pcm.2023.18
Vancouver
Feng Q, Lacey B, Bešević J, Omiyale W, Conroy M, Starkey F, et al. UK biobank: Enhanced assessment of the epidemiology and long-term impact of coronavirus disease-2019. Cambridge Prisms: Precision Medicine. 2023. doi:10.1017/pcm.2023.18
BibTeX
@article{Feng2023,
author = {Feng, Qi and Lacey, Ben and Bešević, Jelena and Omiyale, Wemimo and Conroy, Megan and Starkey, Fenella and Calvin, Catherine and Callen, Howard and Bramley, Laura and Welsh, Samantha and Young, Allen and Effingham, Mark and Young, Alan and Collins, Rory and Holliday, Jo and Allen, Naomi},
title = {UK biobank: Enhanced assessment of the epidemiology and long-term impact of coronavirus disease-2019},
journal = {Cambridge Prisms: Precision Medicine},
year = {2023},
doi = {10.1017/pcm.2023.18}
}
EUVIMED